Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP530952.RARLxtvnbh30s4mNyNbizZxa3rtayVUs8aF6I7wK0rzCA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP530952.RARLxtvnbh30s4mNyNbizZxa3rtayVUs8aF6I7wK0rzCA130_assertion type Assertion NP530952.RARLxtvnbh30s4mNyNbizZxa3rtayVUs8aF6I7wK0rzCA130_head.
- NP530952.RARLxtvnbh30s4mNyNbizZxa3rtayVUs8aF6I7wK0rzCA130_assertion description "[ACE levels in CSF were lower in patients with NMO/NMOs (34.3+/-5.61 ng/ml) than in MS patients (42.5+/-8.19 ng/ml, P(corr)=0.035) and controls (44.7+/-4.02 ng/ml, P(corr)<0.0003) while ACE2 levels were lower in NMO/NMOs (1.13+/-0.49 ng/ml) and MS (1.75+/-0.86 ng/ml) patients than in controls (2.76+/-0.23 ng/ml, P(corr)<0.001 for both).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP530952.RARLxtvnbh30s4mNyNbizZxa3rtayVUs8aF6I7wK0rzCA130_provenance.
- NP530952.RARLxtvnbh30s4mNyNbizZxa3rtayVUs8aF6I7wK0rzCA130_assertion evidence source_evidence_literature NP530952.RARLxtvnbh30s4mNyNbizZxa3rtayVUs8aF6I7wK0rzCA130_provenance.
- NP530952.RARLxtvnbh30s4mNyNbizZxa3rtayVUs8aF6I7wK0rzCA130_assertion SIO_000772 20541774 NP530952.RARLxtvnbh30s4mNyNbizZxa3rtayVUs8aF6I7wK0rzCA130_provenance.
- NP530952.RARLxtvnbh30s4mNyNbizZxa3rtayVUs8aF6I7wK0rzCA130_assertion wasDerivedFrom befree-20150227 NP530952.RARLxtvnbh30s4mNyNbizZxa3rtayVUs8aF6I7wK0rzCA130_provenance.
- NP530952.RARLxtvnbh30s4mNyNbizZxa3rtayVUs8aF6I7wK0rzCA130_assertion wasGeneratedBy ECO_0000203 NP530952.RARLxtvnbh30s4mNyNbizZxa3rtayVUs8aF6I7wK0rzCA130_provenance.